OVARIAN CANCER and US: weight

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label weight. Show all posts
Showing posts with label weight. Show all posts

Sunday, May 27, 2012

Time to Ovarian Cancer Return Not Tied to BMI - in Meeting Coverage, ASCO from MedPage Today



Medical News: Time to Ovarian Cancer Return Not Tied to BMI - in Meeting Coverage, ASCO from MedPage Today


Action Points


  • Note that this study was published as an abstract and will be presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • A study found that obesity did not affect recurrence, time to recurrence, or progression-free survival in women with epithelial ovarian cancer following surgery and adjuvant chemotherapy without evidence of disease during treatment.
  • Note that the approximately one-third of patients who had BMI >30 kg/m2 had similar recurrence rates and time to recurrence as the two-thirds of non-obese patients.

Tuesday, April 03, 2012

Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO Special Articles]



Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO Special Articles]:

pdf (open access)

Purpose
To provide recommendations for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer.

Methods
The American Society of Clinical Oncology convened a Panel of experts in medical and gynecologic oncology, clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient representative. MEDLINE searches identified studies published in English between 1996 and 2010, and a systematic review of the literature was conducted. A majority of studies involved breast, ovarian, colon, and lung cancers. This guideline does not address dosing for novel targeted agents.

Results
Practice pattern studies demonstrate that up to 40% of obese patients receive limited chemotherapy doses that are not based on actual body weight. Concerns about toxicity or overdosing in obese patients with cancer, based on the use of actual body weight, are unfounded.

Recommendations
The Panel recommends that full weight–based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure. There is no evidence that short- or long-term toxicity is increased among obese patients receiving full weight–based doses. Most data indicate that myelosuppression is the same or less pronounced among the obese than the non-obese who are administered full weight–based doses. Clinicians should respond to all treatment-related toxicities in obese patients in the same ways they do for non-obese patients. The use of fixed-dose chemotherapy is rarely justified, but the Panel does recommend fixed dosing for a few select agents. The Panel recommends further research into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese patients with cancer.

Friday, March 30, 2012

Cancerwise: Obesity and Cancer Risk: Our Expert Weighs In



Obesity and Cancer Risk: Our Expert Weighs In: By Jennifer Montgomery, MD Anderson Staff Writer

A new report shows that cancer death rates are still on the decline in the United States, but increasing obesity remains a concern.

The Annual Report to the Nation on the Status of Cancer, released March 28, notes that for more than three decades, too much weight, too little exercise and unhealthy eating habits have been second only to tobacco as preventable causes of disease and death.

Since the 1960s, the report says, tobacco use has declined by one-third, but obesity rates have doubled. According to the report, 2 in 3 adults and 1 in 3 kids are overweight or obese, which places them at risk for not only heart disease and diabetes, but also cancer. After reviewing more than 7,000 studies, the report's researchers have identified six cancers associated with being overweight or obese:
  • Esophageal adenocarcinoma
  • Colon and rectal cancer
  • Kidney cancer
  • Pancreatic cancer
  • Endometrial cancer
  • Breast cancer among postmenopausal women
This review also finds convincing evidence of an association between lack of sufficient physical activity and increased risk of colon cancer. A probable association is cited for post-menopausal breast and endometrial cancers.The report notes that less than half of adults get enough physical activity. Youths get even less. Lorenzo Cohen, Ph.D., professor in the Department of General Oncology and director of MD Anderson's Integrative Medicine Program, shares his reaction to the annual cancer report, as well as suggestions for how people can take action now to reduce obesity and prevent cancer.



The Annual Report to the Nation on the Status of Cancer looks at U.S. cancer numbers from 1975 and 2008. It's a collaboration of researchers from the Centers for Disease Control and Prevention, the North American Association of Central Cancer Registries, the National Cancer Institute and the American Cancer Society.

Additional highlights from the report:

  • Death rates from all cancers combined for men, women and children continued to decline in the United States between 2004 and 2008.
  • New cancer diagnoses among men fell an average of 0.6% per year over the same period. 
  • New cancer diagnoses among women declined 0.5% per year from 1998 through 2006, but rates leveled off from 2006 through 2008.
  • For the second consecutive year, mortality rates for lung cancer have decreased among women. Lung cancer death rates in men have been decreasing since the early 1990s.
  • Breast cancer incidence rates among women declined from 1999 through 2004 and plateaued from 2004 through 2008.
  • Colorectal cancer incidence rates decreased among men and women from 1999 through 2008.
  • Incidence rates of some cancers, including pancreas, kidney, thyroid, liver and melanoma, increased from 1999 through 2008.
  • Among racial and ethnic groups, the highest cancer incidence rates between 2004 and 2008 were among black men and white women. Cancer death rates from 2004 through 2008 were highest among black men and black women, but these groups showed the largest declines between 1999 and 2008, compared with other racial groups.
  • Among children age 19 or younger, cancer incidence rates increased 0.6% per year from 2004 through 2008, while death rates decreased 1.3% per year during the same period.

Wednesday, February 29, 2012

American Institute for Cancer Research (AICR): 2012 Research Conference on Food, Nutrition, Physical Activity and Cancer



2012 AICR Annual Research Conference
on Food, Nutrition, Physical Activity and Cancer
November 1-2 / Washington, DC

About the Conference:

This conference is a unique forum that brings together researchers and clinicians for a two-day program that is dedicated to increasing knowledge, stimulating research and promoting prevention and treatment of cancer through nutrition, physical activity and weight management.

Who Should Attend:

Basic scientists, clinical investigators, epidemiologists, dietitians, nutritionists, policy makers and other health professionals interested in food, nutrition, physical activity and weight management in relation to cancer.

Saturday, January 21, 2012

abstract: Anthropometric Measures (BMI, height, weight gain) and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers



"....Height, weight, and BMI were not associated with the risk of ovarian cancer (P-trend ≥0.15). Also, there was no association between changes in body weight between ages 18-30, or ages 30-40, or ages 18-40 and the risk of ovarian cancer (P-trend ≥0.28). The results from this study suggest that height, weight, or weight gain do not influence the risk of ovarian cancer among carriers of a BRCA1 or BRCA2 mutation."

Wednesday, February 02, 2011

abstract: Anthropometric factors and ovarian cancer risk in the Malmö Diet and Cancer Study



define: anthropometry - The field that involves the measurement of the dimensions and other physical characteristics of people and the application of this information to the design of things they use.
www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm095024.htm

"....Neither height, weight, BMI, body fat percentage, waist- or hip circumference were associated with overall risk, nor with risk for different subtypes, differentiation grade or stage.
Conclusions: These results demonstrate that a high WHR (waist hip ratio) is associated with a decreased risk of EOC. Other anthropometric factors were not associated with EOC risk."

Tuesday, July 20, 2010

Weight, Physical Activity, Diet, and Prognosis in Breast and Gynecologic Cancers --JCO (abstract)



ABSTRACT
Diet, physical activity, and weight may affect prognosis among women who are diagnosed with breast or gynecologic cancer. Observational studies show associations between being overweight or obese and weight gain with several measures of reduced prognosis in women with breast cancer and some suggestion of poor prognosis in underweight women. Observational studies have shown an association between higher levels of physical activity and improved breast cancer–specific and all-cause mortality, although a dose-response relationship has not been established. One large randomized controlled trial reported increased disease-free survival after a mean of 5 years in patients with breast cancer randomly assigned to a low-fat diet versus control. However, another trial of similar size found no effect from a high vegetable/fruit, low-fat diet on breast cancer prognosis. The few reported studies suggest that obesity negatively affects endometrial cancer survival, while the limited data are mixed for associations of weight with ovarian cancer prognosis. Insufficient data exist for assessing associations of weight, physical activity, or diet with prognosis in other gynecologic cancers. Associations of particular micronutrient intake and alcohol use with prognosis are not defined for any of these cancers. The effects of dietary weight loss and increase in physical activity on survival or recurrence in breast and gynecologic cancers are not yet established, and randomized controlled trials are needed for definitive data.

Wednesday, June 09, 2010

Scaling Laws for Plasma Concentrations and Tolerable Doses of Anticancer Drugs -- Cancer Research




Abstract:
General scaling laws are developed for projecting measurements of the plasma concentrations of anticancer drugs from laboratory animals to humans and among humans of different sizes. Associated scaling laws for critical drug doses are established from these laws. Broad categories of single and periodic i.v. bolus dosings are considered. Validity of the relations is shown using measurement from the literature for several well-known cytotoxic agents. The scaling theory is also shown to apply to novel anticancer drugs now available or presently under development, as represented by the p.o. administered prodrug capecitabine, the gene silencing inhibitor zebularine, and the blood vessel inhibitor bevacizumab(Avastin). Scaling considerations for the modern practice of combination chemotherapy are also discussed.